(adsbygoogle = window.adsbygoogle || []).push({});
Moderna shares plunged 12.3% in premarket trading on Thursday after sales of the company’s Covid-19 vaccine fell short of Wall Street analysts’ estimates by more than a billion dollars.
The company reported total revenue of $5 billion for the third quarter of the year, 20% short of the FactSet analyst consensus estimate of $6.2 billion. Spikevax, Moderna‘s (ticker: MRNA) Covid-19 vaccine, is the company’s only product.
The…